A method for treating an immune disease caused by a Th1/Th2 imbalance in favor of a Th2 shift in a subject including administering a composition comprising Lactobacillus plantarum CJLP133 strain KCTC 11403BP to the subject in need thereof.

The present invention provides a use of a substance in the preparation of a product for treating chronic atrophic gastritis, protecting gastric mucosa, treating gastric precancerous lesions, blocking transformation of gastritis into cancer, and preventing occurrence of gastric cancer, the product being one selected from a medicament, a healthcare product and a foodstuff, and the substance being selected from the group consisting of: nuciferin, a nuciferin derivative, a lotus leaf extract, and a mixture of at least two selected from the above substances. The use includes at least one of treating chronic atrophic gastritis, protecting gastric mucosa, blocking transformation of gastritis into cancer, treating gastric precancerous lesions, and preventing occurrence of gastric cancer. In vitro experiments showed that nuciferin can block transformation of gastritis into cancer and cell proliferation. In vivo experiments showed that nuciferin and lotus leaf extract can treat atrophic gastritis in rats (especially chronic atrophic gastritis with intestinal metaplasia or dysplasia), protect rats from gastric mucosal damage and inhibit abnormal proliferation of gastrointestinal stem cells in Drosophila. Clinical tests indicated that lotus leaf extract can improve symptoms and objective indicators in patients with atrophic gastritis or gastric precancerous lesions.

The present invention provides a use of a substance in the preparation of a product for treating chronic atrophic gastritis, protecting gastric mucosa, treating gastric precancerous lesions, blocking transformation of gastritis into cancer, and preventing occurrence of gastric cancer, the product being one selected from a medicament, a healthcare product and a foodstuff, and the substance being selected from the group consisting of: nuciferin, a nuciferin derivative, a lotus leaf extract, and a mixture of at least two selected from the above substances. The use includes at least one of treating chronic atrophic gastritis, protecting gastric mucosa, blocking transformation of gastritis into cancer, treating gastric precancerous lesions, and preventing occurrence of gastric cancer. In vitro experiments showed that nuciferin can block transformation of gastritis into cancer and cell proliferation. In vivo experiments showed that nuciferin and lotus leaf extract can treat atrophic gastritis in rats (especially chronic atrophic gastritis with intestinal metaplasia or dysplasia), protect rats from gastric mucosal damage and inhibit abnormal proliferation of gastrointestinal stem cells in Drosophila. Clinical tests indicated that lotus leaf extract can improve symptoms and objective indicators in patients with atrophic gastritis or gastric precancerous lesions.

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient,

##STR00001##

wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient,

##STR00001##

wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

A composition comprising at least about 25% of a fiber component, by weight of the composition, provides a safe and effective amount of fiber component to a user. A method of producing such a composition is provided. Additionally a method of providing a safe and effective amount of fiber component to a user is provided.

A composition comprising at least about 25% of a fiber component, by weight of the composition, provides a safe and effective amount of fiber component to a user. A method of producing such a composition is provided. Additionally a method of providing a safe and effective amount of fiber component to a user is provided.

Provided are a microorganism as Lactobacillus plantarum having anti-cancer activity, a composition including the same, and a method of preventing or treating a cancer by using the same.